Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06370039 · ClinicalTrials.gov registry record · Phase 2
Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease
A Phase 2 study, sponsored by Invirsa.
- Completed
- Registry status
- Phase 2
- Development phase
- 109
- Enrollment target
NCT06370039 is a Phase 2 study that has completed, run by Invirsa. The registered enrollment target is 109 participants.
The verdict
NCT06370039, a Phase 2 study, has completed, sponsored by Invirsa.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 109 participants
- Enrollment target
Study Summary
Phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during 4-week repeat dosing in subjects with moderate to severe dry eye disease.
Interventions
- DRUG Vehicle
- DRUG INV-102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2024-03-27 |
| Est. Completion | 2024-07-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06370039
The ClinicalTrials.gov registry entry for NCT06370039 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Invirsa, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT06370039 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06370039 about?
NCT06370039 is a clinical study titled "Study of INV-102 Ophthalmic Solution in Adults With Moderate to Severe Dry Eye Disease". Phase 2 study to assess the efficacy of topically administered eyedrops of INV-102 during 4-week repeat dosing in subjects with moderate to severe dry eye disease.
What is the current status of trial NCT06370039?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2024-03-27. Estimated completion is 2024-07-03.
What interventions are being tested in trial NCT06370039?
The interventions under investigation include: Vehicle (DRUG), INV-102 (DRUG).
Who is sponsoring clinical trial NCT06370039?
This trial is sponsored by Invirsa, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.